ALECENSA (alectinib), tyrosine kinase inhibitor

High clinical benefit and minor clinical added value compared to XALKORI as first line treatment of metastatic non-small cell lung cancer with ALK gene rearrangement.

• ALECENSA has been granted marketing authorisation for the first-line treatment in monotherapy of adults suffering from advanced metastatic non-small cell lung cancer (NSCLC) with ALK rearrangement.

• Its superiority over XALKORI(crizotinib) in terms of progression-free survival has been demonstrated, though it is impossible to draw any conclusions concerning overall survival due to the study methodology.

• Its tolerance profile is comparable to crizotinib.

• It is the preferred first-line treatment for this population.